350 rub
Journal №1 for 2014 г.
Article in number:
Biochemical markers of neuroendocrine tumors
Keywords: biochemical markers neuroendocrine tumors diagnosis treatment monitoring
Authors:
N.V. Lyubimova - Dr.Sc. (Biol.), Professor, The N.N. Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences, Moscow
N.E. Kushlinskii - Dr.Sc. (Med.), Professor, Corresponding Member, the N.N. Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences, Moscow
Abstract:
Neuroendocrine tumors (NETs) are derived from the cells of a wide range of organs and characterized by different manifestations. Unlike the other tumors, NETs synthesize a variety of biologically active substances (hormones, peptides, amines), which lead to the development of various clinical syndromes and symptoms. Over the last three decades, the development of sensitive and specific blood plasma and serum assays has facilitated biochemical markers application in NETs diagnosis and monitoring. The best characterized circulated marker that identifies NETs in general is chromogranin A, whereas the individual peptides and amines are specific to certain types of NETs. The review presents main historical and methodological aspects in application of NETs markers. General biological and molecular features of most important circulating markers are characterized. Their utility in diagnosis, monitoring and prognosis for various types of NETs is presented according to the leading investigators and our own results.
Pages: 48-58
References
  1. Ardill J.E.S. Circulating markers for endocrine tumours of gastroenteropancreatic tract // Ann. Cli. Biochem. 2008. V. 45. P. 539-59.
  2. Arnold R., Wilke A., Rinke A. et al. Plasma Chromogranin A as Marker for Survival in Patients With Metastatic Endocrine Gastroenteropancreatic Tumors // Clin. Gastroenterol. Hepatol. 2008. V. 6. P. 820-27.
  3. Aunis D., Metz-Boutigue M.-H. Chromogranins: current concepts. In Book: Chromogranins: Functional and Clinical Aspects. 2000. P. 21-38.
  4. Esparmer V., Avero B. Identification of enteroamine the specific hormone of the enterochromaffine cell system, as 5-hydroxytryptamine // Nature. 1952. V. 169. P. 800-801.
  5. Ghaferi A.A., Chojnacki A., Long W.D., Cameron J.L., Yeo S. Pancreatic VIPomas: Subject Review and One Institutional Experience // J. Gastrointest. Surg. 2008. V. 12. P. 382-93.
  6. de Herder W.W. Biochemistry of neuroendocrine tumours // Best Practice and Clinical endocrinology & Metabolism. 2007. V. 21. № 1. P. 34-41.
  7. Kidd M., Modlin I.M., Mane Sh.M., Camp R.L., Shapiro M.D. Q RT-PCR Detection of Chromogranin A. A new standard in the Identification of Neuroendocrine Tumor Disease // Ann. Surg. 2006. V. 243. P. 273-80.
  8. Korse C.M., Bonfrer J.M., Aaronson N.K., Hart A.A., Taal B.G. Chromogranin A as an alternative to 5-hydroxuindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors // Neuroendocrinology. 2009. V. 89. № 3. P. 296-301.
  9. Lamberts S.W.J., Hofland L.J., Nobels F.R. Neuroendocrine Tumor Markers // Frontiers in Neuroendocrinology. 2001. V. 22. P. 309-39.
  10. Lesurtel M., Soll C., Graf R., Clavien P. Role of serotonin in the hepato-gastrointestinal tract: an old molecule for new perspectives // Cell. Mol. Life Sci. 2008. V. 65. P. 940-52.
  11. Lindholm D.P., Oberg K. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors // Horm. Metab. Res. 2011. V. 43. № 12. P. 832-7.
  12. Nikou G.C., Marinou K., Thomakos P. et al. Chromogranin A levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours // Pancreatology. 2008. V. 8. № 4-5. P. 510-9.
  13. Oberg K. Diagnostic Pathways. Handbook of Gastroenteropancreatic and Thoracic Neuroendocrine Tumors // Published by BIOScietifica UK. 2011. P. 93-114.
  14. Olias G., Viollet C., Kusserow H., Epelbaum J., Meyerhof W. Regulation and function of somatostatin receptors // J. Neurochem. 2004. V. 89. № 5. P. 1057-91.
  15. O-Tool D., Grossman A., Gloss D. et al. Consensus Guidelines For The Standarts Of Care In Neuroendocrine Tumors: Biochemical Markers // Neuroendocrinology. 2009. V. 90. P. 194-202.
  16. Pernow B., Waldenstrom J. Determination of 5-hydroxytryptamine, 5-hydroxy indolacetic acid and histamine in 33 cases of carcinoid tumor (argentafinnoma) // Am. J. Med. 1957. V. 23. P. 16-25.
  17. Ramage J.K., Ahmed A., Ardill J. et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours // Gut. 2012. V. 61. P. 6-32.
  18. Remme C.A., de Groot G.H., Schrijver G. Diagnosis and treatment of VIPoma in female patient // Eur. J. Gastroenterol. Hepatol. 2006. V. 18. P. 93-99.
  19. Rorstad O. Prognostic Indicators for Carcinoid neuroendocrine Tumors of the Gastrointestinal Tract // J. Surg. Oncol. 2005. V. 89. P. 151-160.
  20. Settleman J., Fonseca R., Nolan J., Hogue-Angeletti R.H. Relationship of multiple forms of chromogranin A // A. J. Biol. Chem. 1985. V. 260. P. 1645-51.
  21. Simon J., Aunis D. Biochemistry of the chromogranin A protein family // Biochem. J. 1989. V. 262. P. 1-13.